Mutation of isocitrate dehydrogenase indicates favorable outcomes in pan-cancer immune checkpoint blockade by Zhiyang Huang, Yingying Li, Hong Zhao, Bin Zhao

Subjects: Get full text

VSIG4+ tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1 by Zongfu Pan, Jinming Chen, Tong Xu, Anqi Cai, Bing Han, Ying Li, Ziwen Fang, Dingyi Yu, Shanshan Wang, Junyu Zhou, Yingying Gong, Yulu Che, Xiaozhou Zou, Lei Cheng, Zhuo Tan, Minghua Ge, Ping Huang

Subjects: Get full text

Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable by Wu Helena T., Hsu Vanessa, Win Shwe, Xing Yan

Subjects: Get full text

Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations by Sophia Kreft, Tommaso Bosetti, Rebecca Lee, Paul Lorigan

Subjects: Get full text

Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives by Yunxiang Hu, Yunxiang Hu, Rui Yang, Shuai Ni, Shuai Ni, Zefeng Song

Subjects: Get full text

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma by Parissa Tabrizian, Rebecca Marino, Sherrie Bhoori, Marcus Zeitlhoefler, Neil Mehta, Vanessa Banz, Salvatore Gruttadauria, Massimo Iavarone, Chiara Mazzarelli, Nicolò Simonotti, Francis Yao, Vincenzo Mazzaferro, Josep M. Llovet

Subjects: Get full text

Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review by Xiuyue Man, Hong Wang, Chen Chen, Xiaofeng Cong, Lemeng Sun, Xueru Sun, Chen Chen, Jing Zhang, Lei Yang

Subjects: “…immune checkpoint inhibitor-associated myocarditis…”
Get full text

Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Ph... by Su H, Shang X, Liu H, Wang Y, Yu Y, Xu Y, Jiang K, Feng F

Subjects: Get full text

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab by Meng Wu, Claudia A.M. Fulgenzi, Antonio D’Alessio, Alessio Cortellini, Ciro Celsa, Giulia F. Manfredi, Bernardo Stefanini, Y. Linda Wu, Yi-Hsiang Huang, Anwaar Saeed, Angelo Pirozzi, Tiziana Pressiani, Lorenza Rimassa, Martin Schoenlein, Kornelius Schulze, Johann von Felden, Yehia Mohamed, Ahmed O. Kaseb, Arndt Vogel, Natascha Roehlen, Marianna Silletta, Naoshi Nishida, Masatoshi Kudo, Caterina Vivaldi, Lorenz Balcar, Bernhard Scheiner, Matthias Pinter, Amit G. Singal, Joshua Glover, Susanna Ulahannan, Fredrich Foerster, Arndt Weinmann, Peter R. Galle, Neehar D. Parikh, Wei-Fan Hsu, Alessandro Parisi, Hong Jae Chon, David J. Pinato, Celina Ang

Subjects: Get full text

Multi-omics analysis reveals the sensitivity of immunotherapy for unresectable non-small cell lung cancer by Rui Wu, Kunchen Wei, Xingshuai Huang, Yinge Zhou, Xiao Feng, Xin Dong, Hao Tang

Subjects: Get full text

Inosine enhances the efficacy of immune‐checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study by Haiqing Zhao, Wei Zhang, Yuting Lu, Yin Dong, Zhihao He, Hongchao Zhen, Qin Li

Subjects: Get full text

Ginseng polysaccharides circumvent acquired resistance to anti-PD-1 immunotherapy in patients with non-small cell lung cancer by Jumin Huang, Ziming Wang, Feng Li, Huiting Wang, Yang Xiang, Runze Li, Chun Xie, Yuwei Wang, Zhihong Jiang, Yabing Cao, Wenhua Liang, Elaine Lai-Han Leung

Subjects: “…Immune checkpoint inhibitors…”
Get full text

Case report: A severe myositis mimicking bulbar palsy after administration of immune checkpoint inhibitors by Philippe Rochigneux, Philippe Rochigneux, Alexandre Bertucci, Elika Loir, Alexia Mattei, Danielle Robert, Michael Dassa, Brice Chanez, Mikael Ebbo, Lea Gaigne, Anne Sophie Chretien, Giovanni Corazza, Giovanni Corazza, Nicolas Schleinitz

Subjects: Get full text

Identifying factors for pembrolizumab eligibility in head and neck cancer by Satoru Miyamaru, Daizo Murakami, Kohei Nishimoto, Yorihisa Orita

Subjects: Get full text

Prognostic value of body adipose tissue parameters in cancer patients treated with immune checkpoint inhibitors by Yan Li, Yean Yu, Kun Lv, Rongjuan Ge, Xie Xie

Subjects: Get full text

The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study by Keiichiro Suminaga, Takashi Nomizo, Hironori Yoshida, Hiroaki Ozasa

Subjects: Get full text

A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops by Ayaka Kawaguchi, Hayato Tanaka, Hitoshi Tabuchi, Kei Nakai, Atsuki Fukushima

Subjects: Get full text

Six events that shaped antibody approvals in oncology by Suman Paul, Suman Paul, Shibin Zhou, Shibin Zhou

Subjects: Get full text

Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single... by Yingyi Li, Yuqin Cao, Xipeng Wang, Chengqiang Li, Liqin Zhao, Hecheng Li

Subjects: Get full text

Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort by Hilin Yildirim, Anke Richters, Adriaan D. Bins, Arnoud W. Postema, Maureen J.B. Aarts, Martijn G.H. van Oijen, Patricia J. Zondervan, Katja K.H. Aben

Subjects: Get full text